Kaminetsky and Himes et al. used it in patients with IL-2R-positive cutaneous T cell lymphoma (CTCL), reaching an overall response of 36% [113]. This evidence concerns the gene IL2RA and primary cutaneous T-cell non-Hodgkin lymphoma.